NOVENTRA PHARMA – TIRZEPATIDE 30 mg
R1 750,00
Dual GIP/GLP-1 receptor agonist Used for weight loss and type 2
diabetes management
• Works by slowing digestion, reducing appetite, improving blood sugar.
• Self-mix vials allow flexible dosing (you measure exact mg per injection).
• Use an insulin syringe to draw up your weekly dose.
• Discard vial 30–45 days after reconstitution,
even if not empty.
• Store unused powder vials in a cool, dry place
until mixed.
Description
Insulin syringe units
Week 1 2.5 mg 16.5 units
Week 2 5 mg 33 units
Week 3 5 mg 33 units
Week 4 7.5 mg 50 units
Week 5 7.5 mg 50 units
Maintenance 7.5 mg 50 units
This is a transcription of the product advertisement, not a verified prescription or dosing recommendation.
Please note: The advertised mixing instructions and dosing should be independently checked. The product’s sterility, authenticity, concentration and suitability must be verified by a qualified healthcare professional before use.
Tirzepatide can cause nausea, vomiting, diarrhoea, constipation and other adverse effects. Dose escalation should be individualised and medically supervised.
Reviews
There are no reviews yet.